Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person The following ALK mutants and fusion proteins are sensitive ...
| Class:Id | Summation:9713418 |
|---|---|
| _displayName | The following ALK mutants and fusion proteins are sensitive ... |
| _timestamp | 2023-10-14 19:29:19 |
| created | [InstanceEdit:9713417] Rothfels, Karen, 2021-01-26 |
| modified | [InstanceEdit:9715236] Rothfels, Karen, 2021-02-17 [InstanceEdit:9716606] Rothfels, Karen, 2021-02-22 [InstanceEdit:9724129] Rothfels, Karen, 2021-03-22 [InstanceEdit:9729687] Rothfels, Karen, 2021-05-03 [InstanceEdit:9851215] Rothfels, Karen, 2023-10-14 |
| text | The following ALK mutants and fusion proteins are sensitive to these type I tyrosine kinase inhibitors: crizotinib: ALK F1174V: Ceccon et al, 2015 ALK L1198F: Chuang et al, 2019; Ceccon et al, 2015 BCL11A(1-219)InsDHPPA-ALK(1058-1620): Tian et al, 2017 BIRC6(1-958)-ALK(1058-1620): Shan et al, 2015 EIF2AK3(30-144)-ALK(1058-1620): Ali et al, 2016 EML4(1-223)-ALK(1059-1620): Ali et al, 2016 EML4(1-223)insKMSTREKNSQV-ALK(1059-1620): Ali et al, 2016 EML4(1-486)-ALK(1058-1620): Ali et al, 2016; Hrustanovic et al, 2015; Katayama et al, 2011 FN1(32-1201)-ALK(1022-1620): Ren et al, 2012 HIP1(1-1019)-ALK(1058-1620): Ou et al, 2014 HIP1(1-963)-ALK(1058-1620): Hong et al, 2014 HIP1(1-719)InsL-ALK(1059-1620): Fang et al, 2014 NPM1(1-117)-ALK(1058-1620): Prokoph et al, 2020 PPM1B (1-282)-ALK(1058-1620): Ali et al, 2016 PRKAR1A(1-183)-ALK(1058-1620): Ali et al, 2016 STRN(1-137)-ALK(1058-1620): Kelly et al, 2014 NVP-TAE684: ALK F1174L: George et al, 2008; Heuckmann et al, 2011 ALK V1180L: Katayama et al, 2014 ALK L1196M: Heuckmann et al, 2011 ALK L1196Q: Ceccon et al, 2013 ALK G1269S: Heuckmann, 2011 ALK R1275Q: George, 2008 CLTC(2-1634)-ALK(1059-1620): Cerchietti et al, 2011 EML4(1-223)insKMSTREKNSQV -ALK(1059-1620): Heuckmann, 2011 FN1(32-1201)-ALK(1022-1620): Ren et al, 2012 NPM1(1-117)-ALK(1058-1620): Galkin et al, 2007 STRN(1-137)-ALK(1058-1620): Kelly et al, 2014 ceritinib: ALK I1171T: Friboulet et al, 2014; Katayama et al, 2014 ALK F1174V: Ceccon et al, 2015 ALK V1180L: Katayama et al, 2014 ALK S1206Y: Friboulet et al, 2014; ALK G1269A: Friboulet et al, 2014; EML4(1-486)-ALK(1058-1620): Hrustanovic et al, 2015 brigatinib: ALK F1174V: Ceccon et al, 2015 ALK V1180L: Katayama et al, 2014 ALK L1196Q: Ceccon et al, 2013 NPM1(1-117)-ALK(1058-1620): Ceccon et al, 2015 alectinib: ALK F1174I: Ou et al, 2016 ALK F1174L: Ou et al, 2016 ALK F1174V: Ou et al, 2016; Ceccon et al, 2015 (moderate) EML4(1-223)-ALK(1059-1620): Ou et al, 2014 EML4(1-223)insKMSTREKNSQV-ALK(1059-1620): Ou et al, 2014 EML4(1-486)-ALK(1058-1620): Davare et al, 2015 HIP1(1-1019)-ALK(1058-1620):Ou et al, 2014 ASP3026: ALK V1180L: Katayama et al, 2014 Entrectinib: ALK C1156Y: Ardini et al, 2016 ALK L1196M: Ardini et al, 2016 EML4(1-223)-ALK(1059-1620): Ardini et al, 2016 EML4(1-223)insKMSTREKNSQV-ALK(1059-1620): Ardini et al, 2016 EML4(1-486)-ALK(1058-1620): Ardini et al, 2016 NPM1(1-117)-ALK(1058-1620): Ardini et al, 2016 |
| (summation) | [Reaction:9700131] ALK mutants bind type I TKIs [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by The following ALK mutants and fusion proteins are sensitive ... (9713418)
